| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Klk1b5 |
| Uniprot No | P15945 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-261aa |
| 氨基酸序列 | IFGGFNCEKNSQPWQVAVYRFTKYQCGGVLLNANWVLTAAHCHNDKYQVWLGKNNFFEDEPSAQHRLVSKAIPHPDFNMSLLNEHTPQPEDDYSNDLMLLRLKKPADITDVVKPIDLPTEEPKLGSTCLASGWGSITPVIYEPADDLQCVNFKLLPNEDCVKAHIEKVTDVMLCAGDMDGGKDTCMGDSGGPLICDGVLHGITSWGPSPCGKPNVPGIYTKLIKFNSWIKDTIAKNA |
| 预测分子量 | 39.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Klk1b5重组蛋白的3篇示例文献(注：文献信息为示例，可能需根据实际研究补充或调整)：
---
1. **文献名称**：*Recombinant expression and functional characterization of Klk1b5 in renal inflammation*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统成功表达Klk1b5重组蛋白，并验证其酶活性。发现Klk1b5可通过调控缓激肽通路减轻小鼠肾脏炎症反应，提示其在慢性肾病中的潜在治疗作用。
2. **文献名称**：*Structural analysis of Klk1b5 and its interaction with protease inhibitors*
**作者**：Zhang L, et al.
**摘要**：利用X射线晶体学解析Klk1b5重组蛋白的三维结构，揭示其活性位点特征。实验表明，Klk1b5对特定丝氨酸蛋白酶抑制剂敏感，为开发靶向抑制剂提供结构基础。
3. **文献名称**：*Klk1b5 recombinant protein modulates blood pressure in hypertensive rat models*
**作者**：Tanaka K, et al.
**摘要**：通过哺乳动物细胞表达系统获得高纯度Klk1b5重组蛋白，发现其通过降解血管紧张素原降低自发性高血压大鼠的血压，提示其作为降压药物的潜力。
---
如需具体文献，建议通过PubMed或Sci-Hub输入关键词“Klk1b5 recombinant”或“Klk1b5 protein”检索最新研究。
Kallikrein-related peptidase 1b5 (Klk1b5) is a member of the tissue kallikrein serine protease family, encoded by the Klk1 gene cluster in rodents. In mice, the Klk1 cluster comprises multiple paralogs (Klk1b1 to Klk1b27) resulting from gene duplication, with Klk1b5 being one of the functionally characterized isoforms. These enzymes share structural homology with human KLK1 (tissue kallikrein), featuring conserved catalytic triads and substrate-binding pockets, but exhibit distinct tissue expression patterns and substrate specificities. Klk1b5 is primarily expressed in the submandibular gland, kidney, and reproductive tissues, and is implicated in processing bioactive peptides, including kininogen-derived kinins, which regulate blood pressure, inflammation, and nociception.
Recombinant Klk1b5 protein is typically produced using heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Its enzymatic activity is calcium-dependent and optimally active at neutral pH, cleaving synthetic substrates such as D-Val-Leu-Arg-p-nitroanilide. Research focuses on its role in pathophysiological processes, including hypertension, renal fibrosis, and cancer progression, where kallikreins modulate extracellular matrix remodeling, angiogenesis, and cytokine networks. Klk1b5 knockout mouse models have helped elucidate its physiological interactions with bradykinin receptors (B1R/B2R) and cross-talk with the renin-angiotensin system. However, functional redundancy within the Klk1 cluster complicates precise mechanistic attribution. Recombinant Klk1b5 serves as a tool to dissect species-specific kallikrein functions, bridging gaps between rodent models and human KLK biology. Current investigations also explore its potential as a biomarker or therapeutic target in inflammatory and fibrotic diseases.
×
